Hot Investor Mandate 3: New Corporate VC of Health Insurance Company Invests Strategically in Digital Health

~ Next Phase Admin ~ Leave a comment

A $50 million venture fund established by a health insurance firm aims to develop a portfolio of investments that, as a whole, focus on improving the national health care market, enhance the core business of the company and generate revenue.

These strategic investments are expected to be integrated into the company as part of its overall long-term strategy. The firm prefers to syndicate with a strong lead investor in a financing round and expects to make 5 – 7 new investments of $0.5-2 million in the coming year. The firm considers opportunities across the US and around the world with preference given to companies in the middle of the country.

The new corporate VC fund is interested in digital health technologies and care delivery models that can improve healthcare. The firm prefers products with prototype and customer traction.

The firm would like to be a strategic partner, as a payer, for startups. The firm prefers early stage teams backed by experienced management, supported by reputable early stage VC and/or angel groups that have a history of follow-on investments in Series A and B.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Research Institution Partners with Investment Firm to Invest $150 Million in Regenerative Medicine Companies

~ Next Phase Admin ~ Leave a comment

An investment firm with offices in the US and UK is partnering with a research organization to raise a $150 million fund focused on Regenerative Medicine (RM). Within RM, 80% of the fund will be towards immunotherapies, cell and gene therapies while the remaining 20% of the fund will be towards enabling-technologies that move RM forward in commercialization and medicine. The firm is looking to build a portfolio of 10-15 early stage RM companies, investing up to $10 million per deal with an initial investment of $1-3 million. The firm prefers to lead investments, though is willing to co-invest. The partnership recently launched the building of cell manufacturing and process manufacturing facilities for GMP, process development, and vector manufacturing that will enable the optimized production of cell lines and tissues necessary for early clinical development of RM technologies. All companies the firm invests in will have the valuable opportunity and prioritized access to the facility in developing their technology. The firm invests globally in RM companies, particularly those RM companies open to leveraging the existing infrastructure local to the firm’s partner organization.

The firm focuses exclusively on regenerative medicine, including stem cells, cell therapies, immunotherapies, and tissue engineering. The firm is interested in RM therapeutics, and is actively looking at several immunotherapies, such as those involving T-cells, dendritic cells, and/or checkpoint inhibitors. The firm is open to any indication in the therapeutic and medical device space, as long as the underlying RM technology is robust, and has demonstrated efficacy that is not incremental, but rather a dramatic change in the way the disease is currently treated. The firm invests in early projects, primarily from the pre-clinical stage through Phase II.

The firm is looking for compelling RM technologies, and is prepared to build or augment the management team and/or board of a company, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Look Who’s Coming To RESI on MaRS

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Director of Research, LSN

With RESI heading to Toronto for the first time, LSN has been delighted to find that many investors are interested in coming to MaRS to get involved in Toronto’s healthcare innovation hub. Ranging from local Ontario funds to firms from the far side of the world, these investors will gather on June 23rd to meet with startup companies from Canada and beyond. If you’d like to join us at RESI on MaRS to book meetings with these investors and more, register here.

RESI on MaRS Confirmed Investors 05-03-16

Looking For Capital? Avoid These 10 Fundraising Pitfalls

~ Next Phase Admin ~ Leave a comment

By Danielle Silva, VP of Business Development, LSN

Danielle 10*10Raising a financing round for a life science company is a long and challenging process. Unfortunately, some fundraising CEOs make it harder by making these common mistakes along the way. From overloading investors with too much information up front, to failing to do their homework on investors prior to reaching out, this presentation covers the most common errors we’ve seen out there on the road. An efficient and successful raise depends on avoiding these mistakes.

 

Perspective and Advice on Raising Medical Device Capital

~ Next Phase Admin ~ Leave a comment

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Fundraising for a traditional medical device in the past several years has been tough, and it’s not getting any easier. New, groundbreaking therapeutic technologies and the explosion of health IT/digital health solutions has prevented a large portion of venture (and corporate) dollars from making their way into companies developing medical devices that require FDA approval, and don’t have some type of software or data component. In addition to “sexier” technologies wooing venture and strategic investors, some other difficult realities for medical devices include a poor exit environment, lower returns (as a sector) compared to biopharma and health IT and the fact that reimbursement still remains a formidable challenge. All of that aside, there is still a need in the healthcare arena for innovative medical devices.

In our second RESI conference of 2016, held at the TMCx accelerator, an experienced group of early-stage medical device investors discussed the sector’s current and future outlook, the Texas healthcare ecosystem and shared their insights on how entrepreneurs developing these products can successfully navigate the investment landscape. Moderated by Angela Shah, Editor, Xconomy, panelists include:

To hear directly from the investors, watch the RESI video recap here:

Hot Investor Mandate 1: Evergreen Corporate VC Seeks Therapeutics in Phase I-II

~ Next Phase Admin ~ Leave a comment

A corporate venture fund located in Europe has an evergreen structure that allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically around €10 million with reserves to follow, and the firm prefers to take above 10% ownership. The fund invests primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals. The firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Family Office Seeks Medical Devices, Healthcare IT, and Surgical Tools

~ Next Phase Admin ~ Leave a comment

A privately funded investment firm based in Canada focuses on making direct investments in the following business sectors: medical technology, medical clinics, healthcare IT and healthcare real estate. In medtech, the firm seeks to invest in seed stage companies. The firm looks to partner and fund scientific founders to launch a new company and will primarily invest in the seed stage round. The firm typically allocates $100K-$200K, and will syndicate with other investors outside of their region (including Australia) to invest in larger rounds of $500K or more. The firm has physician, medical experience, particularly in the surgical field. The firm invests globally and is currently seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in medical devices and healthcare IT. The firm is opportunistic in terms of the class of device and indications, and has particular interest in surgical devices and tools. The firm is additionally interested in digital health. The firm prefers to invest in the pre-prototype stage and with particular preference to very early-stage preclinical technology.

The firm is seeking startups with a maximum $5M pre-money valuation and will invest in pre-revenue companies. The firm is very hands-on after an investment, opening up and bringing their network to their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com